Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2023 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
17 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
3 Mar 22
Current reports
8-K
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan
12 Mar 24
8-K
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
5 Mar 24
8-K
Other Events
4 Mar 24
8-K
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
29 Nov 23
8-K
Departure of Directors or Certain Officers
27 Nov 23
8-K
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Oct 23
8-K
Departure of Directors or Certain Officers
7 Sep 23
8-K
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Gossamer Bio Announces $212 Million Private Placement Financing
20 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
5 Mar 24
424B3
Prospectus supplement
28 Aug 23
S-3
Shelf registration
18 Aug 23
RW
Registration withdrawal request
18 Aug 23
S-3ASR
Automatic shelf registration
17 Aug 23
D
$212.10 mm in equity / options, sold $212.10 mm, 70 investors
7 Aug 23
S-3ASR
Automatic shelf registration
9 Aug 22
D
$120.04M in equity, sold $120.04M, 23 investors
18 Jul 22
S-8
Registration of securities for employees
3 Mar 22
S-3ASR
Automatic shelf registration
3 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
9 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
Other
EFFECT
Notice of effectiveness
29 Aug 23
CORRESP
Correspondence with SEC
24 Aug 23
UPLOAD
Letter from SEC
24 Aug 23
EFFECT
Notice of effectiveness
8 Feb 19
CT ORDER
Confidential treatment order
8 Feb 19
CERT
Certification of approval for exchange listing
5 Feb 19
CORRESP
Correspondence with SEC
5 Feb 19
CORRESP
Correspondence with SEC
5 Feb 19
CORRESP
Correspondence with SEC
26 Dec 18
CORRESP
Correspondence with SEC
21 Dec 18
Ownership